micro-community-banner
  • Saved

3yr
Preview of the 2022 American Heart Association Scientific Sessions

The American Heart Association (AHA) Scientific Sessions 2022 are being held at McCormick Place Convention Center in Chicago and virtually from Nov. 5 to 7, 2022. In-person and virtual attendees have access to scientific sessions, abstract presentations/posters, on-demand content, networking opportunities, and more. The meeting boasts 1,000 abstracts, 500 exhibitors, and 15,000 participants.



Click above for a preview of the upcoming content curated by our team of analysts.

 

  • Saved

3yr
Preview of the 2022 American Heart Association Scientific Sessions

The American Heart Association (AHA) Scientific Sessions 2022 are being held at McCormick Place Convention Center in Chicago and virtually from Nov. 5 to 7, 2022. In-person and virtual attendees have access to scientific sessions, abstract presentations/posters, on-demand content, networking opportunities, and more. The meeting boasts 1,000 abstracts, 500 exhibitors, and 15,000 participants.



Click above for a preview of the upcoming content curated by our team of analysts.

 

  • Saved

3yr
Simulation study on LDL cholesterol target attainment, treatment costs, and ASCVD events with bempedoic acid in patients at high and very-high cardiovascular risk

Simulation study on LDL cholesterol target attainment, treatment costs, and ASCVD events with bempedoic acid in patients at high and very-high cardiovascular risk

Source : https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0276898

Background and aims The LDL cholesterol (LDL-C) treatment goals recommended by the 2019 ESC/EAS guidelines are only achieved in a minority of patients. The study objective was to estimate the...



Conclusions: A considerably larger proportion of cardiovascular high- and very-high-risk patients can achieve guideline-recommended LDL-C goals with escalated lipid-lowering medication. Bempedoic acid is projected to substantially decrease the need for PCSK9 inhibitor treatment to achieve LDL-C targets, associated with reduced drug costs...

  • Saved

3yr

I am interested in hearing opinions on next steps and management for a patient, 55 year old male who is an ultra-marathoner and when he is not doing that he is cycling, kayaking, skiing, etc. Referred for mild abnormalities on his ECG. Echo shows a mildly dilated LV with normal wall thickness, EF 50% without focal/segmental wall motion...

  • Saved

3yr
Predictive value of 10-year atherosclerotic cardiovascular disease risk equations from the China-PAR for new-onset lower extremity peripheral artery disease

Predictive value of 10-year atherosclerotic cardiovascular disease risk equations from the China-PAR for new-onset lower extremity peripheral artery disease

Source : https://www.frontiersin.org/articles/10.3389/fcvm.2022.933054/full

Lower extremity peripheral artery disease (LEPAD) is a common and serious health-threatening disease. The aim of this study was to evaluate the predictive value of 10-year atherosclerotic cardiovascular disease (ASCVD)...


Conclusions: 10-year China-PAR ASCVD risk independently predicted the risk of new-onset LEPAD in a Chinese community-based population, indicating the importance of polyvascular diseases (PVDs) and the intrinsic interactions of its components.